Publicaciones en colaboración con investigadores/as de Essen University Hospital (117)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology

  2. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology, Vol. 86, Núm. 1, pp. 4-9

  3. Diversity of kidney care referral pathways in national child health systems of 48 European countries

    Frontiers in Pediatrics, Vol. 12

  4. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

  5. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

    Clinical Genitourinary Cancer

  6. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, Núm. 3, pp. 219-244

  7. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

    The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322

  8. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

    Leukemia

  9. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters

    European urology oncology, Vol. 7, Núm. 2, pp. 231-240

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia, Vol. 37, Núm. 7, pp. 1511-1520

  3. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

    Haematologica, Vol. 108, Núm. 1, pp. 34-41

  4. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  5. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  6. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  7. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  8. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

  9. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

  10. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 79-92

  11. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746